112th Day Of Lockdown

Maharashtra26766514900710695 Tamil Nadu147324973102099 Delhi115346932363446 Karnataka4407717391846 Gujarat43723305552070 Uttar Pradesh3972424981983 Telangana3774524840375 Andhra Pradesh3301917467408 West Bengal3283819931980 Rajasthan2557119169524 Haryana2262817090312 Madhya Pradesh1900513575673 Bihar1885313019143 Assam178081217451 Odisha14280986496 Jammu and Kashmir111736223195 Kerala8931443835 Punjab85115663213 Chhatisgarh4379327520 Jharkhand4225242836 Uttarakhand3686286750 Goa2753160718 Tripura218315382 Manipur167210200 Puducherry153182918 Himachal Pradesh130993810 Nagaland8963460 Chandigarh60044610 Arunachal Pradesh3871453 Meghalaya318462 Mizoram2381590 Sikkim211860
Lifestyle Health and Wellbeing 27 Sep 2018 Scientists develop d ...

Scientists develop drug that could treat Parkinson's disease

Published Sep 27, 2018, 12:20 pm IST
Updated Sep 27, 2018, 12:20 pm IST
Parkinson's disease is associated with serious disease complications.
Scientists develop drug that could treat Parkinson's disease. (Photo: Pixabay)
 Scientists develop drug that could treat Parkinson's disease. (Photo: Pixabay)

Washington D.C. - In the wake of media and public reports about increased mortality, researchers found a new drug for treating Parkinson's disease psychosis (PDP).

Parkinson's disease (PD) is a complex neurodegenerative disorder. Symptoms generally develop slowly over the years, and typically affect movement, balance and walking. However, cognitive dysfunction, such as PDP, often appears in the later stages of the disease and is a leading contributor to patients being admitted to nursing homes.


Scientists at the UC San Diego School of Medicine conducted a retrospective study of qualifying patients, concluding that the new drug, pimavanserin (marketed as Nuplazid), did not pose a statistically significant greater risk of death.

PD in itself is not fatal but is associated with serious disease complications, making the condition the 14th leading cause of death.

Using anonymised medical records of patients diagnosed with Parkinson's disease, researchers singled out 676 cases that met the study criteria of having a PD diagnosis and being prescribed pimavanserin, quetiapine (an antipsychotic drug marketed as Seroquel) or both.


The Food and Drug Administration approved for PDP after designating it a "breakthrough therapy." The expedited approval followed a single, six-week clinical trial of 199 participants.

As the first drug approved to treat hallucinations and delusions associated with PDP, Nuplazid was immediately popular. But lingering concerns about limited clinical testing were exacerbated by reports of increased adverse effects in patients using pimavanserin, "including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue."


The researchers did note an increased risk of mortality -- 74 per cent -- in the quetiapine-only group compared with individuals, not on these medications and a trend toward increased risk in the combination therapy group. "It's reasonable to assume, however, that individuals requiring these medications have greater disease severity and are at a higher risk of complications and death," said the study's corresponding author, Fatta B. Nahab.

"Our findings provide the largest comparative report of mortality risk in PDP to date," said Nahab, "but there were limitations to our study based on its design and nature. We did not find any new or unexpected concerns about the use of pimavanserin in the treatment of PDP, which may provide some reassurance to clinicians, patients and families. But more work is needed to better evaluate factors like disease severity and cause of death to improve our understanding of the potential risks of treating PDP."


The findings appeared in the Journal of Neurology.